-
Tumor Genomics: Customizing Treatments for Deadly Prostate Cancer
Share this:
A new study at Mayo Clinic is using genomic sequencing to develop customized treatments for men with castration-resistant prostate cancer, a progressive and incurable stage of prostate cancer, which no longer responds to hormone therapies that stop or slow testosterone production.
Oncologist and principal investigator of the Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) study, Manish Kohli, M.D., says, “Men with castration-resistant prostate cancer have abysmal survival rates, typically living an average of two years once hormone therapies fail." Dr. Kohli says the poor prognosis for men with this cancer highlights the need for studies like PROMOTE, which seek to match new targeted drugs with the genomic characteristics of individual patients’ tumors.
Click here for news release.
Watch this educational animation about pharmacogenomics:
http://www.youtube.com/watch?v=fGjG_9EEeeA
Share this:
Related articles
ROCHESTER, Minn. — In an academic-industrial collaboration, Mayo Clinic is assessing in a clinical trial a new radiotracer in pancreatic cancer imaging. As part of the ...
Radon is an odorless, invisible radioactive gas. It's naturally released from rocks, soil and water — and it can get trapped inside your home, office ...
January is Cervical Health Awareness Month, which makes this a good time to learn about the connection between HPV and cervical cancer. Approximately 13,000 new cases of cervical ...